Slingshot members are tracking this event:

Seattle Genetics to report phase 1 clinical data from ASG-15ME and ASG-22ME at the ASCO annual meeting being held June 3 to 7, 2016. These programs are in development in collaboration with Astellas for solid tumors, notably bladder cancer.

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
SGEN Community voting in process
ALPMY Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 06, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Asg-15me, Asg-22me, Asco, Bladder Cancer, Solid Tumors